Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12087496 | 0.92 | HDAC1 (0.52) | MMEHDAC1CYP17A1CYP3A4CYP19A1 | |
| SCHEMBL1310411 | 0.86 | EPHX2 (0.45) | HDAC1MGLLHDAC2MAOB | |
| SCHEMBL3913014 | 0.84 | MAOA (0.47) | HDAC1CYP19A1MAOB | |
| SCHEMBL28011617 | 0.83 | FFAR1 (0.56) | MMEHDAC1CYP17A1CYP3A4CYP19A1 | |
| Hydrochloric Acid SCHEMBL7999705 | 0.83 | MAOA (0.49) | HDAC1CYP19A1MAOB | |
| SCHEMBL1351101 | 0.81 | TSHR (0.48) | CYP19A1MAOB | |
| SCHEMBL3466545 | 0.81 | MMP12 (0.54) | MMEMGLLFFAR1 | |
| SCHEMBL16035296 | 0.81 | MGLL (0.47) | HDAC1MGLLHDAC2FFAR1 | |
| SCHEMBL6194181 | 0.80 | HDAC6 (0.50) | HDAC1CYP19A1MAOB | |
| SCHEMBL20628670 | 0.80 | HDAC2 (0.65) | HDAC1MGLLHDAC2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2011143105-A1 | BIFUNCTIONAL QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, MRGPRX2 | MME 3067/4885HDAC1 851/4885MGLL 3320/4885 |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, HRH2 | MME 3325/4885HDAC1 914/4885MGLL 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.